Aurelio Mendoza MA

Language: Spanish
References: 22
Page: 18-27
PDF size: 199.25 Kb.

ABSTRACT

Antibiotic action against bacteria is based on their ability to bind to certain targets of the bacterial structure, inactivating the target. In spite of this, as the time of generalized antibiotic usage goes by, these drugs lose their efficiency in such a way that they become useless for clinical practice. Bacterial antibiotic resistance is due to both mutations and the acquisition –from other bacteria– of genes encoding certain proteins that make bacteria resistant by different mechanisms. Antibiotic resistance in Mycobacterium tuberculosis isonly due to mutations while in Staphylococcus aureus and other taxa it is mainly due to genes acquired from other bacteria. More than 2 million people around the world die every year from antibiotic-unresponsive infections. Resistance has been exacerbated because of the huge amounts of antibioticsused worldwide for several purposes. Physicians should be better informed about resistance in order to reduce antibiotic prescription when such treatment is not necessary. Moreover, doctors should also teach their patients using the information available about adverse effects of antibiotics, including diarrhea, vaginal candidiasis, hepatic affections, and probably cancer. The massive use of substances capable of efficiently diminishing infectious processes started in the 1940’s, beginning the antibiotic era. Even though sulfa drugs had been used to treat infections, the antibiotic efficient against severe infections, as those produced by the fearsome Staphylococcus aureus, was penicillin. This pioneer antibiotic was introduced in the market in 1943 with an effect that seemed magic, because it was efficient in all the infectious processes caused by such biological agent. Nevertheless, just three years later strains resistant to this antibiotic were detected and the selection was so intense that in 1950 40% of strains were resistant and by 1960 the percentage increased to 80%. The aim of this article is to highlight the importance that antibiotic bacterial resistance has acquired in the last decades, its causes, and some strategies that may be followed in order to control it.

REFERENCES

1. Drake JW, Charlesworth D, Crow FC. Rates of spontaneous mutation. Genetics. 1998;148:1667-86.

2. Barry CE, Cheung MS. New tactics against tuberculosis. Sci Amer. 2009;300:56-63.

3. Quinto informe de la Secretaría de Salud Pública. Capítulo 3. Subsecretaría de Prevención y Promoción de la Salud, 2005.

4. Boletín de Práctica Médica Efectiva. Tuberculosis pulmonar. Diagnóstico y Tratamiento. Instituto Nacional de Salud Pública. Secretaría de Salud de México. Noviembre 2006.

5. Quiros-Roldán E, Airoldi M, Moretti F, Carosi G. Bases moleculares de resistencia de Mycobacterium tuberculosis. Rev Diag Biol. 2001;Vol 50. En línea.

6. Chambers HF. The changing epidemiology of Staphylococcus aureus. Emerg Infect Dis. 2001;7:178-82.

7. Plorde J J, Sherris J C. Staphylococcal resistance to antibiotics: origin, measurement, and epidemiology. Ann N Y Acad Sci. 1974;236:413-34.

8. Weigel LM, Clewell DB, Gill SR y col. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science. 2003;302:1569-71.

9. Sánchez M, de la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA. 2010;303:2260-4.

10. Dorit RL. Routes of resistance. Amer Scient. 2009;97:20-7.

11. Cowan C, Jones HA, Kaya YK, Perry RD, Straley SC. Invasion of epithelial cells by Yersinia pestis: evidence for a Y. pestis-specific invasin. Infect Immun. 2000;68:4523-30.

12. Viboud GI, Bliska JB. Yersinia outer proteins: role in modulation Annu Rev Microbiol. 2005;59: 69.89.

13. Klasschik S, Lehmann LE, Raadts A, Book M, Hoeft A, Stuber F. Real-time PCR for detection of gram-positive and gramnegative bacteria. J Clin Microbiol. 2002;40:4304-7.

14. Rolain JM, Mallet MN, Fournier PE, Raoult D. Real-time PCR for universal antibiotic-susceptibility testing. J Antimicrob Chemother. 2004;54:538-41.

15. Smith D L, Laxminarayan R. Human interventions on the evolution of host-bacterium interactions. En: Baquero F, Nombela C, Cassell GH, Gutiérrez-Fuentes JA (Eds). Evolutionary Biology of Bacterial and Fungal Pathogens. ASM Press, Washington, D. C. 2008: 51-62.

16. Ong S, Nakase J, Moran GJ, Karras DJ, Kuehnert MJ, Talan DA. Antibiotic use for emergency department patients with upper respiratory infections: prescribing practices, patient expectations, and patient satisfaction. Ann Emerg Med. 2007;50:213-20.

17. Bartlett JG. Antibiotic-associated diarrhea. New Engl J Med. 2002;346:334-9.

18. Pirotta MV, Garland SM. Genital Candida species detected and after treatment with Antibiotics. J Clin Microbiol. 2006; 44:3213-7.

19. Westphal JF, Vetter D, Brogard JM. Hepatic side-effects of antibiotics. J Antimicrob Chemother. 1994;33:387-401.

20. Annamari K, Rissanen H, Klaukka T, et al. Antibiotic use predicts an increased risk of cancer. Int J Cancer. 2008; 123:2152-5.